Revolution Medicines (RVMD) Total Non-Current Liabilities (2019 - 2026)

Revolution Medicines' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $746.9 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 160.76% year-over-year to $746.9 million; the TTM figure through Mar 2026 stood at $746.9 million (up 160.76% YoY), while the FY2025 annual figure was $722.0 million, up 149.05% from the prior year.
• Total Non-Current Liabilities was $746.9 million for Q1 2026 at Revolution Medicines, up from $722.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $746.9 million in Q1 2026 to a low of $119.3 million in Q1 2023.
• Historically, Total Non-Current Liabilities has averaged $293.6 million across 5 years, with a median of $188.2 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities retreated 8.31% in 2023, then jumped 232.78% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $126.4 million in 2022, then soared by 85.11% to $234.1 million in 2023, then advanced by 23.86% to $289.9 million in 2024, then jumped by 149.05% to $722.0 million in 2025, then grew by 3.45% to $746.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $746.9 million (Q1 2026), $722.0 million (Q4 2025), and $649.1 million (Q3 2025), per Business Quant data.